Xu X, Feng J, Luo Y, He X, Zang J, Huang D
Institute of Pediatrics, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, Chongqing 400014, China.
Department of Cardiology, Children's Hospital of Chongqing Medical University, Key Laboratory of Children's Important Organ Development and Diseases of Chongqing Municipal Health Commission, National Clinical Key Cardiovascular Specialty, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, Chongqing 400014, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2024 Feb 20;44(2):201-209. doi: 10.12122/j.issn.1673-4254.2024.02.01.
To investigate the protective effect of NDUFA13 protein against acute liver injury and liver fibrosis in mice and explore the possible mechanisms.
BALB/C mice (7 to 8 weeks old) were divided into normal group, CCl group, CCl+AAV-NC group and CCl+AAV-NDU13 group (=18). Mouse models of liver fibrosis were established by intraperitoneal injection of CCl twice a week for 3, 5 or 7 weeks, and the recombinant virus AAV8-TBG-NC or AAV8-TBG-NDUFA13 was injected via the tail vein 7-10 days prior to CCl injection. After the treatments, pathological changes in the liver of the mice were observed using HE and Masson staining. Hepatic expression levels of NDUFA13 and α-SMA were detected with Western blotting, and the coexpression of NDUFA13 and NLRP3, TNF-α and IL-1β, and α-SMA and collagen Ⅲ was analyzed with immunofluorescence assay.
HE and Masson staining showed deranged liver architecture, necrotic hepatocytes and obvious inflammatory infiltration and collagen fiber deposition in mice with CCl injection ( < 0.001). NDUFA13 expression markedly decreased in CCl-treated mice ( < 0.001), while a significant reduction in inflammatory aggregation and fibrosis was observed in mice with AAV-mediated NDUFA13 overexpression ( < 0.001). In CCl+AAV-NDU13 group, immunofluorescence assay revealed markedly weakened activation of NLRP3 inflammasomes ( < 0.001), significantly decreased TNF-α and IL-1β secretion ( < 0.001), and inhibited hepatic stellate cell activation ( < 0.05) and collagen formation in the liver ( < 0.001).
Mitochondrial NDUFA13 overexpression in hepatocytes protects against CCl- induced liver fibrosis in mice by inhibiting activation of NLRP3 signaling.
探讨 NDUFA13 蛋白对小鼠急性肝损伤和肝纤维化的保护作用,并探索其可能的机制。
将 7 至 8 周龄的 BALB/C 小鼠分为正常组、CCl 组、CCl+AAV-NC 组和 CCl+AAV-NDU13 组(每组 n = 18)。通过每周两次腹腔注射 CCl 共 3、5 或 7 周建立肝纤维化小鼠模型,并在注射 CCl 前 7 - 10 天经尾静脉注射重组病毒 AAV8-TBG-NC 或 AAV8-TBG-NDUFA13。处理后,采用 HE 和 Masson 染色观察小鼠肝脏的病理变化。用 Western blotting 检测肝脏中 NDUFA13 和α-SMA 的表达水平,并用免疫荧光分析法分析 NDUFA13 与 NLRP3、TNF-α与 IL-1β以及α-SMA 与胶原蛋白Ⅲ的共表达情况。
HE 和 Masson 染色显示,注射 CCl 的小鼠肝脏结构紊乱、肝细胞坏死、明显的炎症浸润和胶原纤维沉积(P < 0.001)。CCl 处理的小鼠中 NDUFA13 表达明显降低(P < 0.001),而在 AAV 介导的 NDUFA13 过表达的小鼠中观察到炎症聚集和纤维化显著减少(P < 0.001)。在 CCl+AAV-NDU13 组中,免疫荧光分析显示 NLRP3 炎性小体的激活明显减弱(P < 0.001),TNF-α和 IL-1β分泌显著减少(P < 0.001),肝星状细胞激活受到抑制(P < 0.05),肝脏中的胶原形成受到抑制(P < 0.001)。
肝细胞中线粒体 NDUFA13 过表达通过抑制 NLRP3 信号通路的激活来保护小鼠免受 CCl 诱导的肝纤维化。